Display options
Cite
Nair A, Veronese M, Xu X, et al. Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease. EJNMMI Res. 2016;6(1):72doi: 10.1186/s13550-016-0226-3.
Nair, A., Veronese, M., Xu, X., Curtis, C., Turkheimer, F., Howard, R., & Reeves, S. (2016). Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease. EJNMMI research, 6(1), 72. https://doi.org/10.1186/s13550-016-0226-3
Nair, Akshay, et al. "Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease." EJNMMI research vol. 6,1 (2016): 72. doi: https://doi.org/10.1186/s13550-016-0226-3
Nair A, Veronese M, Xu X, Curtis C, Turkheimer F, Howard R, Reeves S. Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease. EJNMMI Res. 2016 Dec;6(1):72. doi: 10.1186/s13550-016-0226-3. Epub 2016 Sep 27. PMID: 27678494; PMCID: PMC5039146.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2016 Dec;6(1):72. doi: 10.1186/s13550-016-0226-3. Epub 2016 Sep 27.

Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease.

EJNMMI research

Akshay Nair, Mattia Veronese, Xiaohui Xu, Charles Curtis, Federico Turkheimer, Robert Howard, Suzanne Reeves

Affiliations

  1. UCL Huntington's Disease Research Group, 2nd floor, Russell Square House, 10-12 Russell Square, London, WC1B 5EH, UK. [email protected].
  2. Centre for Neuroimaging Sciences, IoPPN, King's College London, Box PO89, De Crespigny Park, London, SE5 8AF, UK.
  3. MRC Social, Genetic and Developmental Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London, SE5 8EF, UK.
  4. NIHR Biomedical Research Centre for Mental Health, Maudsley Hospital and Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, UK.
  5. Division of Psychiatry, University College London, 6th Floor, Wings A and B, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK.

PMID: 27678494 PMCID: PMC5039146 DOI: 10.1186/s13550-016-0226-3

Abstract

PURPOSE: In order to maximise the utility of [(11)C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer's disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability of three SUV-based metrics was assessed in AD patients over 12 weeks.

METHODS: Five patients with mild AD and the high-affinity binding TSPO genotype underwent two [(11)C]-PBR28 PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to cerebellar grey matter (SUVRC) and SUV normalised to whole brain activity (SUVRWB) in nine cortical and limbic regions of interest was assessed using the absolute variability and the intraclass correlation coefficient.

RESULTS: Of the three measures, SUVRWB performed best overall, showing low absolute variability (mean -0.13 %, SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94) but also high variability (mean -1.24 %, SD 7.28 %). By comparison, the SUVRC showed higher variability (mean -3.98 %, SD 7.07 %) and low reliability (ICC = 0.65).

CONCLUSIONS: In this AD sample, we found that SUV-derived metrics of [(11)C]-PBR28 binding showed high stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of [(11)C]-PBR28. Pending further validation of SUV-based measures of [(11)C]-PBR28, semi-quantitative methods of [(11)C]-PBR28 analysis may prove useful in longitudinal studies of AD.

Keywords: Alzheimer’s; Dementia; Inflammation; Microglia; Positron emission tomography

References

  1. Neuroimage. 2007 May 15;36(1):28-37 - PubMed
  2. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  3. J Nucl Med. 2007 Jan;48(1):158-67 - PubMed
  4. Biochem Soc Trans. 2015 Aug;43(4):586-92 - PubMed
  5. Neuroimage Clin. 2015 Jan 19;7:409-14 - PubMed
  6. J Nucl Med. 2015 May;56(5):701-6 - PubMed
  7. Alzheimers Dement. 2015 Sep;11(9):1110-20 - PubMed
  8. Int Psychogeriatr. 1997;9 Suppl 1:87-94; discussion 143-50 - PubMed
  9. J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5 - PubMed
  10. Nat Rev Immunol. 2014 Jul;14 (7):463-77 - PubMed
  11. Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1081-92 - PubMed
  12. J Cereb Blood Flow Metab. 2014 Jun;34(6):989-94 - PubMed
  13. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):173-83 - PubMed
  14. Multimodal Brain Image Anal (2013). 2013;8159:150-158 - PubMed
  15. Pharmacol Ther. 2008 Apr;118(1):1-17 - PubMed

Publication Types

Grant support